EUCTR2013-000055-41-ES进行中（未招募）1 期
Assessment of an Education and Guidance programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN) - AEGEA
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,217
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Signed Written Informed Consent.
- •- Patients with diagnosed non-valvular AF (documented by 12-lead ECG or Holter recording) and eligible for OAC therapy.
- •- Presence of at least one of the following risk factors for stroke:
- •prior stroke or transient ischaemic attack (TIA)
- •age ?75 years
- •hypertension
- •diabetes mellitus
- •symptomatic heart failure (NYHA Class ? II)
- •- Must be able to self-administer treatment.
- •- Either VKA treated or VKA naive. Patients treated with VKA should have received the VKA treatment for ? 6 months. VKA naïve patients should not have received VKA treatment for more than 30 days within the last 12 months.
- •- Patients previously treated with ASA for stroke prevention are allowed (and will switch to Apixaban).
- •- Subject Re-enrollment: This study does not permit the re-enrollment of a subject that has discontinued the study as a pre-treatment failure.
- •- Men and women ? 18 years of age.
- •- Women of childbearing potential (WOCBP) must use method(s) of contraception based on the tables in Appendix 4.
- •- WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study medication.
- •- Women must not be breastfeeding.
- •- Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year.
- •- Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile; see Section 3.3.3 for the definition of WOCBP) and azoospermic men do not require contraception.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 333
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 779
排除标准
- •1) Target Disease Exceptions
- •a) Atrial fibrillation or flutter due to reversible causes (e.g. thyrotoxicosis, pericarditis)
- •b) Clinically significant (moderate or severe) mitral stenosis
- •c) Cardiac valvular disease requiring surgery
- •d) Planned atrial fibrillation ablation procedure to be performed during study period.
- •2) Medical History and Concurrent Diseases
- •a) Conditions other than atrial fibrillation that require chronic anticoagulation (e.g., prosthetic mechanical heart valve, venous thromboembolism; also see Section 3.4, Concomitant Treatments).
- •b) Patient with serious bleeding in the last 6 months or with a lesion or condition at high risk
- •of bleeding such as:
- •? Active peptic ulcer disease, current or recent gastrointestinal ulceration
- •?Known or suspected oesophageal varices
- •?Recent ischemic stroke (within 7 days)
- •?Recent brain or spinal injury or intracranial haemorrhage
- •?Recent brain, spinal or ophthalmic surgery
- •?Arteriovenous malformations,
- •?Vascular aneurysms
- •?Major intraspinal or intracerebral vascular abnormalities
- •?Documented hemorrhagic tendencies or blood dyscrasias
- •?Presence of malignant neoplasms at high risk of bleeding
- •c) Persistent, uncontrolled hypertension (systolic BP > 180 mm Hg, and/or diastolic BP > 100 mm Hg)
- •d) Active infective endocarditis
- •e) Hepatic disease associated with coagulopathy and clinically relevant bleeding risk
- •f) Active alcohol or drug abuse, or psychosocial reasons that make study participation impractical.
- •g) Severe co-morbid condition with life expectancy ?1 year
- •3) Physical and Laboratory Test Findings
- •a) Severe renal insufficiency (creatinine clearance must be calculated in all patients; any patient with a calculated creatinine clearance <15 ml/min is excluded) or patients undergoing dialysis.
- •b) ALT (alanine aminotransferase) or AST (aspartate aminotransferase) > 2 times upper limit of normal or a total bilirubin > 1.5 times upper limit of normal (unless an alternative causative factor [e.g., Gilbert?s syndrome] is identified)
- •c) Haemoglobin < 9 g/dL
- •d) Platelet count < 100,000/mm3
- •4) Allergies and Adverse Drug Reaction
- •a) Allergy or adverse reaction to apixaban or any of the excipients
- •5) Sex and Reproductive Status
- •a) Women who are pregnant or breast feeding
- •b) Women of child bearing potential (WOCBP, see Section 3.3.3 for definition) who are unwilling to meet the study requirements for pregnancy testing or are unwilling or unable to use an acceptable method to avoid pregnancy.
- •c) Sexually active fertile men not willing to use effective birth control if their partners are WOCBP
- •6) Prohibited Treatments and/or Therapies
- •a) See Section 3.4.1 (Prohibited and/or Restricted Treatments) for therapies which are
- •prohibited at study entry
- •b) Required treatment with ASA > 165 mg/day
- •c) Simultaneous treatment with a thienopyridine (e.g., clopidogrel, ticlopidine; see Section 3.4.2.1, Acetylsalicylic acid [ASA] and Thienopyridines) or prasugrel or ticagrelor
- •d) Planned major surgery or/and invasive procedure
- •e) Planned atrial fibrillation or flutter ablation procedure
- •7) Other Exclusion Criteria
- •a) Prisoners or subjects who are involuntarily incarcerated
- •b) Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness
- •c) Use of an unapproved, investigational drug or device within the past 30 days or prior participation into an apixaban clinical study
- •d) Inability to comply with protocol visit and activity requirements
- •e) Subjects unable
研究者
相似试验
撤回
4 期
Assessment of an Education and Guidance programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation.stroke prevention in Atrial Fibrillation stroke prevention in cardiac arrhythmia10007521NL-OMON38431Bristol-Myers Squibb40
进行中（未招募）
不适用
Assessment of an Education and Guidance programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)EUCTR2013-000055-41-ITBristol-Myers Squibb International Corporation1,112
进行中（未招募）
1 期
Assessment of an Education and Guidance programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)Patients with diagnosed non-valvular atrial fibrillation or atrial flutter with at least one risk factor for stroke and indicated for oral anticoagulant.MedDRA version: 17.0 Level: PT Classification code 10003658 Term: Atrial fibrillation System Organ Class: 10007541 - Cardiac disordersEUCTR2013-000055-41-GBBristol-Myers Squibb International Corporation1,217
进行中（未招募）
不适用
Assessment of an Education and Guidance programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)EUCTR2013-000055-41-BEBristol-Myers Squibb International Corporation1,112
进行中（未招募）
1 期
Assessment of an Education and Guidance programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)Patients with diagnosed non-valvular atrial fibrillation or atrial flutterwith at least one risk factor for stroke and indicated for oralanticoagulant.MedDRA version: 17.1Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersEUCTR2013-000055-41-DEBristol-Myers Squibb International Corporation1,112